Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock

About this update from Fulcrum Therapeutics, Inc.

[{"type":"text","content":"CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (“Fulcrum”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that it has commenced an underwritten public offering of $150.0 million of shares of its common stock. Fulcrum also intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of shares of its common stock offered in the proposed public offering. All of the shares in the proposed offering are to be sold by Fulcrum. J.P. Morgan, Leerink Partners, and Cantor are acting as book-running managers for the proposed offering. Oppenheimer & Co. and Truist Securities are also acting as book-running managers for the proposed offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering. The shares of common stock are being offered by Fulcrum pursuant to an effective shelf registration statement that was previously filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 27, 2024 and declared effective by the SEC on April 25, 2024. The proposed offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Fulcrum currently intends to use the net proceeds from the sale of securities offered in the proposed public offering primarily for general corporate purposes, which may include working capital and capital expenditures, research and development expenses, including to fund clinical trials, regulatory submissions, commercialization, discovery and additional preclinical research and development of additional product candidates and platform enhancement, general and administrative expenses, and potential acquisitions of, or investments in, companies, technologies, products or assets that complement its business. When available, copies of the preliminary prospectus supplement and acco...

More updates from Fulcrum Therapeutics, Inc.